Literature DB >> 10773489

Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia.

J E Kristiansen1, J B Hansen.   

Abstract

A series of neuroleptic agents and their structural isomers have been tested as inhibitors of HIV-replication. At non-toxic concentrations, cis (Z)- and trans (E)-flupentixol and several derivatives of the 5HT-uptake-inhibitors paroxetine and femoxetine, inhibit HIV-1 replication. The findings indicated that these compounds could be used in combination with other anti-retroviral therapy in HIV-1 infected patients with AIDS-related dementia.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10773489     DOI： 10.1016/s0924-8579(99)00157-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Drug treatment of depression in HIV-positive patients : safety considerations.

Authors:  Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

3.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

Review 4.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

5.  Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression.

Authors:  Chiara Cecchelli; Giacomo Grassi; Stefano Pallanti
Journal:  Case Rep Med       Date:  2010-03-30

6.  Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.

Authors:  Kelly A Meulendyke; Suzanne E Queen; Elizabeth L Engle; Erin N Shirk; Jiayang Liu; Joseph P Steiner; Avindra Nath; Patrick M Tarwater; David R Graham; Joseph L Mankowski; M Christine Zink
Journal:  J Neurovirol       Date:  2014-09-17       Impact factor: 2.643

Review 7.  Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Authors:  Yaser Pashaei
Journal:  J Clin Neurosci       Date:  2021-03-19       Impact factor: 1.961

Review 8.  A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.

Authors:  Marianne Ø Poulsen; Sujata G Dastidar; Debalina Sinha Roy; Shauroseni Palchoudhuri; Jette Elisabeth H Kristiansen; Stephen J Fey
Journal:  Molecules       Date:  2021-12-29       Impact factor: 4.411

Review 9.  Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.

Authors:  Vitória Segabinazzi Foletto; Taciéli Fagundes da Rosa; Marissa Bolson Serafin; Rosmari Hörner
Journal:  Eur J Clin Pharmacol       Date:  2022-08-09       Impact factor: 3.064
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.